Chronic obstructive pulmonary disease with pulmonary hypertension
Conditions
Interventions
Experimental group:Conventional treatment of Western medicine combined with Tianfu cough and asthma capsules
Control group:Conventional treatment of Western medicine combined
Sponsors
The First Affiliated Hospital Of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for COPD; 2. Those who meet the diagnostic criteria for PH and are judged to have non-severe PH (PVR <=5WU) in the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the Diagnosis and Treatment of Pulmonary Arterial Hypertension, and whose WHO pulmonary hypertension functional grade is less than IV, and whose PH is secondary to COPD, belongs to COPD-PH; 3. Age range: 40–75 years old (including 40 and 75), gender is not limited; 4. Voluntary test, good compliance and signed informed consent; 5. Those who meet all of the above conditions.
Exclusion criteria
Exclusion criteria: 1. does not meet the above diagnostic criteria; 2. Pulmonary hypertension caused by chronic thromboembolic pulmonary hypertension and/or other pulmonary artery obstructive lesions; 3. Those with allergies or allergies and intolerances to the drug Tianfu cough and asthma capsules and the pharmaceutical ingredients in this study, such as aconite, ephedra, banxia, etc.; 4. Patients whose condition requires non-invasive or invasive assisted ventilation; 5. Patients with complications such as mental problems, immunosuppression, severe cardiovascular and cerebrovascular diseases, malignant tumors or MODS; 6. Have a history of alcohol, drug abuse, or other conditions that affect the trial according to the judgment of the investigator; 7. Women who are pregnant, lactating or planning to have children in the near future; 8. Those who have participated in other clinical trials in the past 3 months; 9. The 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the Diagnosis and Treatment of Pulmonary Arterial Hypertension were determined to be severe PH (PVR >5WU). Those with WHO pulmonary arterial hypertension functional grade greater than grade III; 10. Other reasons that the investigator considers inappropriate for enrollment; 11. Those who meet at least one of the above conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ELISA and qPCR were used to detect changes in the expression levels of peripheral serum DNMT3a, GSDMD and pyroptosis pathway-related proteins;Pulmonary systolic blood pressure;Lung function;Ultrasound to detect changes in pulmonary artery blood flow and vascular structure and function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Subject's 6-min walking distance (6MWD);Dyspnea score; | — |
Countries
China
Contacts
Public ContactWang Peng
The First Affiliated Hospital Of Guangzhou Medical University
Outcome results
None listed